Archive for the ‘IHIF Press Releases’ Category

Trade Mission to 2017 Zhejiang Medical Expo

May 25, 2017

Turnpike Trade Mission
Zhejiang Medical Equipment Expo/Health Services Promotion Expo
Zhejiang Province, China
September 10-17, 2017

Hangzhou ExpoThe Hangzhou International Expo Center will be the main venue for the 2017 Health Expo in Hangzhou, the capital of Zhejiang province.(Photo/Xinhua)

The state trade association members of the Turnpike Partnership and their members are invited to participate in a trade mission to Zhejiang Province, China. Coordinated by the Indiana Health Industry Forum (IHIF) and their agent in China, Pacific World Trade (PWT), the mission will attend the “2017 Health Expo”, a joint meeting of the Zhejiang Medical Equipment Expo and the Health Services Promotion Expo. The exhibition and conference will be held in the newly appointed G-20 conference center in Hangzhou, Zhejiang, China.

Mission Focus

Expo 2

The Medical Products Exhibition provides procurement units across many different hospital and healthcare facility levels with an efficient and convenient platform
for viewing new devices and technologies.

This mission will focus on making introductions and developing commercial partnerships in China for U.S. companies engaged in the design, development, appointment/outfitting of hospitals and healthcare facilities, and related training and services.

  • Facility design and operation
  • Digital technologies
  • Hospital Equipment and Supplies
  • Training (healthcare and equipment)
  • Services

Mission Services
Companies participating in the mission will be provided with 1:1 meetings coordinated by PWT and the Zhejiang Health Services Promotion Council, a presentation opportunity to conference attendees, and participation in a Turnpike booth at the Expo.

Agenda*
September 10 – Depart US
September 11 – Arrive in Hangzhou, Zhejiang Province.
September 12 – Briefing/reception, potential for pre-arranged meetings/tours
September 13 – 16 – 2017 Healthcare Expo: exhibition, presentations, meetings
September 17 – Return to U.S.
*subject to change depending on availability

Mission fees and registration
Delegates are responsible for their own travel/accommodation arrangements. There will be a reserved block of hotel rooms for the mission, near the exhibition center. PWT will provide assistance with letters of invitation for visas, and have staff available on the ground in China. Other anticipated costs may include in-country transportation and translation services.

Mission participation fee: $2,995/organization*
*Mission fee subject to change. Rate includes shared costs for a 3mX3m Turnpike exhibition booth and rental of facilities for company presentations. Requires a minimum of four company participants.

Registration Deadline: August 1, 2017
For more information or to register for the mission, please contact the Indiana Health Industry Forum at info@ihif.org.  Download Mission Brochure.  Download 2017 ZIHIE Brochure.

About Zhejiang: Zhejiang province is located on the southeast coast of China, to the south of Shanghai. It is divided into eleven prefecture-level divisions, nine prefecture level cities and two sub-provincial cities (the capital city of Hangzhou and city of Ningbo). Zhejiang is considered a relatively wealthy province and has been consistently in the top 5 out of 34 provinces in terms of nominal total GDP and GDP per capita. In 2015, it contributed 7% of China’s total GDP. Zhejiang has a population of 55 million people with 1,049 hospitals across the province.

Zhejiang province is the largest consumer of medical devices in China and serves as a “showcase” for the total market. 30,000 professionals will attend the Expo. The annual transaction value at the Expo is over $175 million or about 20% of the total market value.

About the Conference: After two successful ZIHIE Expos, in September 2017, a more comprehensive and innovative Expo will be held at the new Hangzhou International Expo Center. With hundreds of exhibitors and thousands of their products and services from across the world, ZIHIE has become the largest health brand exposition for Zhejiang province. 800 hospitals will be represented by executive staff as part of the provincial Hospital Association annual meeting.

About IHIF/PWT: The Indiana Health Industry Forum and Pacific World Trade work together to help Indiana health science companies explore market opportunities in China and specifically work with governmental and private organizations in Zhejiang Province, Indiana’s sister-state. Leveraging the 30+ year relationship PWT has fostered on behalf of Indiana, combined with export guidance and counseling, member companies of IHIF can be assured of a well-researched and supported introduction to the Chinese market.

About the Turnpike Partnership: The Turnpike Partnership is an international network of health science industry associations focused on patient-driven public policy and innovation services. The Turnpike Partnership brings together health science associations and their members with industry leaders, research universities, startup companies, mentors, and related national trade associations. The Turnpike model erases geo-political boundaries and focuses on getting innovation in front of the people who can connect it most quickly to patients. Organized and led at the state/grassroots level, the Partnership provides a collaborative, viable, sustainable business model and support system.

Advertisements

IHIF Signs Partnership Agreement With Scottish Lifesciences Association

May 17, 2017

 Builds New Market Opportunities for State Industry Members

Contact: Kristin Jones, IHIF, kjones@ihif.org +1-317-752-9809

(Indianapolis,IN USA and Edinburgh, Scotland UK- May 16, 2017) — The Indiana Health Industry Forum (IHIF) and the Scottish Lifesciences Association (SLA) have signed a Memorandum of Understanding to share member benefits between the two organizations.  IHIF and SLA share the same essential vision with regards to creation and maintenance of an environment that nurtures and supports life sciences companies.  The objectives are to foster innovation and valuable, dynamic links between US-based member companies of IHIF and Scotland-based member companies of SLA.

 

According to Scott Johnstone, CEO of the SLA, “IHIF and SLA intend to represent the USA and EU to each other as practical for the mutual benefit of our organizations and our member companies.  Through this relationship, we intend to increase the visibility, sales, investment, regulation, and innovation prospects for our member companies”.

 

Both organizations are members of the multi-state Turnpike Partnership, an innovation-driven network of resources and organizations built to support and enhance the life sciences industry. Scotland is a key international partner with a life sciences cluster of similar size and scope to Indiana’s.

 

Building on an already strong trade relationship, “IHIF and SLA were able to come together through the Turnpike Partnership and build an alliance that will directly benefit our members”, said Kristin Jones, President and CEO of IHIF.  “The partnership with SLA is a further expansion of our international network and will give our members strategic access to UK and European markets at a time of dynamic change.  We also look forward to working with members of SLA as they build their business networks and explore opportunities in the U.S.”

 

The MOU was signed at the 2017 Derby Summit, an annual event for the Kentucky Life Sciences Council.  The Scottish delegation also visited Boston and IHIF representatives attended the May 11 Spring Members Meeting for the SLA in Glasgow, Scotland.

 

About SLA

With 135 member companies and organisations, the SLA is the voice of Scotland’s vibrant life sciences industries to investors, NHSScotland, the Scottish and UK Governments, and the wider community.  The SLA is driven by and network with its members through 14 Special Interest Groups and 4 sub-groups.  The SLA helps to grow members’ businesses, and engage with the NHS and Government to grow the life sciences sector in Scotland.

 

For more information: http://www.scottishlifesciencesassociation.org.uk

 

About IHIF

IHIF is a statewide trade association representing Indiana’s health science business community.  The diverse members of the Indiana Health Industry Forum generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.

 

For more information: http://www.ihif.org

SLA Mou

Kristin Jones (IHIF) and Scott Johnstone (SLA) sign agreement to trade member services.

###

FAST BioMedical Raises $8 Million as part of Series A2 Financing Round

May 3, 2017

Carmel, Indiana – May 3, 2017 – FAST BioMedical, Inc. today announced it has secured $8 million of additional financing.  $5 million comes from a Series A2 Financing led by one new investor, F&M Investment Office.  This financing augments $3 million of grant funding received as a competing renewal award from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.  The proceeds will primarily be used to advance clinical trials of the company’s technology as well as to hire additional talent and advance the company’s global patent portfolio.

“This financing is an important and validating step to continue our progress,” said Joe Muldoon, FAST BioMedical Chief Executive Officer.  “We have already begun adding talent to the team, and are excited about their ability to immediately add value”

“FAST BioMedical has enormous potential to serve large unmet medical needs with its innovative technology,” said Mr. McClure, President of F&M Investment Office.  “We are delighted to partner with them, and see great promise in the ability to favorably impact critical patient care. ”

About FAST BioMedical

FAST BioMedical is a private, clinical-stage medical technology company in Carmel, Indiana.  The company’s globally patented first-in-class technologies directly measure blood volume and kidney function in a clinically viable way.  This has the potential for profound impact on care of congestive heart failure, major surgery, sepsis, critical care, and kidney disease patients.   The company has been financially supported by the NIH, Elevate Ventures, the Indiana 21st Century Fund, Rose-Hulman Ventures, BioCrossroads, Indiana University Medical Group, The Purdue Foundry Fund, Ellipsis Ventures, StepStone Partners, and private family office investors. The FDA has determined the company’s technology met the requirements for an Expedited Review.

These products are investigational and not yet approved for human use.

For more information, please visit www.FASTBioMedical.com

IHIF is a Proud Partner in National Health IT Week

August 21, 2016

This September, IHIF — as a partner in the advancement of health information technology to help improve healthcare —is a Proud Partner in National Health IT Week.  National Health IT Week is the premier event offering all healthcare stakeholders an opportunity to unite under one banner, expressing the benefits that health information technology (IT) brings to U.S. healthcare. “The Value of Health IT.”

Comprehensive health care reform is not possible without system-wide adoption of health information technology, which improves the quality of healthcare delivery, increases patient safety, decreases medical errors, and strengthens the interaction between patients and healthcare providers.

With Meaningful Use now providing the way forward, eligible providers across the country increasingly understand the benefits for themselves and their patients, and are adopting Meaningful Use compliant electronic health records.

Initiated in 2006 by the Healthcare Information and Management Systems Society (HIMSS), National Health IT Week has emerged as a landmark occasion for using health IT as part of the overall solution to improve America’s healthcare as a bipartisan, federally led, market driven initiative.

The Week consists of events across the country, including National Health IT Weekparticipants —vendors, provider organizations, payers, pharmaceutical/biotech companies, government agencies, industry/professional associations, research foundations, and consumer protection groups— all working together to elevate national attention to the advantages of advancing health IT.

View our full list of partners and updates on the Week’s events. Working together with our growing coalition of stakeholders, IHIF is helping to transform healthcare for all.

IHIF Welcomes New Members

August 3, 2016

Quality Connection

Quality Connection is a labor management partnership comprised of 100 union electrical contractors and nearly 3,000 International Brotherhood of Electrical Workers (IBEW) #481 electrical workers. Together labor and management provide the needed expertise, highly trained workforce, safety and dedication to help build many of Central Indiana’s premiere education, health care, utility sites and logistics projects. The unique business relationship spans more than 50 years and represents a strong tradition of quality electrical construction, progressive labor negotiations and community service. With an unprecedented commitment to workforce training, job safety and worker standards. Quality Connection . . .Quality Work, Customer Connected. Learn more at www.qcindy.com

NeRX Biosciences

One of the most effective chemotherapeutics used in the treatment of cancer continues to be the DNA damaging agent cisplatin. Pioneered by our Medical Advisor, Dr. Larry Einhorn at the Indiana University School of Medicine for the treatment of testicular cancer, cure rates now exceed 90% for this cancer. This represents one of the few shining stories since the “War on Cancer” was initiated in the early 1970’s. Unfortunately, cisplatin is considerably less effective in treating other cancers but remain first-line treatment for lung and ovarian cancer. NERx Biosciences co-founder and CSO, Dr. John Turchi has been studying the biology and biochemistry of cisplatin for 25 years and in 2005 was recruited to the Indiana University Cancer Center where advances in his laboratory have paved the way for recapitulating the successes of platinum treatment for testicular cancer in lung and ovarian cancer.

NĒRx Biosciences was established in 2009 to capitalize on these advances and discoveries to develop novel therapeutics to enable the effective treatment of highly prevalent and difficult to treat cancers including lung and ovarian. Learn more at www.nerxbiosciences.com.

 

Azenix/Futago Corporation

 Researching and developing advanced process technology and design manufacturing plan cooperated with Futago LLC.

KinaSense

KinaSense is developing cell-based assays used in preclinical drug discovery to identify and characeterize new compounds for oncology. Our assays are faster, less expensive, and have more physiological relevance than traditional methods used in target validation and potency studies, allowing earlier decision making fro progressing compounds into animal studies.Learn more at www.kinasense.com.

MorNuCo

MorNuCo, Inc. is a biotech company focused on age related diseases with an emphasis on cancer detection. Learn more at www.mornuco.com.

Phytoption LLC

Phytoption LLC is an innovation company developing propriatory ingredients to improve drug bioavailability, food quality, and cosmetics functionality. It offers patented technology and ingredients to pharmaceutical, food, or cosmetic industrial partners.

Safekeeping (2)

Safekeeping is a moblie application that delivers health and lifestyle information to family members of patients in care facilities.Learn more at www.safekeepingapp.com.

BIO Press Release: National Bioscience Report Shows Industry Creating Jobs and Driving Innovation

June 7, 2016
BIO Logo Horizontal RGB
 
NEWS RELEASE
1201 Maryland Avenue, SW l Ste. 900 l Washington, D.C. l 20024 l 202-962-9200
Web: www.bio.org       Blog: www.biotech-now.org  Twitter: @IAmBiotech
 
For Immediate Release  
   
Contact:      George Goodno 202-962666       Ryan Helwing 800-832-1296

National Bioscience Report Shows Industry Creating Jobs and Driving Innovation

Bioscience industry contributing to U.S. economic growth and improving quality of life for patients
Indiana Maintains Recognition for Being a Large, Diverse Cluster

 

San Francisco, CA (June 7, 2016)-A study released today at the BIO International Convention shows increased employment within the U.S. bioscience industry for the last four consecutive years.  The report also shows impressive bioscience industry strength and resilience, with employment growth of nearly 10 percent since 2001. Among technology sectors the bioscience industry has been a leading performer over this period.

The report, The Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life 2016, finds U.S. bioscience firms employ 1.66 million people, a figure that includes nearly 147,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $94,543 in 2014. These earnings are $43,000 greater, on average, than the overall U.S. private sector wage of $51,148.

The report further shows that since 2012, the bioscience industry has grown by 2.2 percent with four of its five major subsectors contributing to this overall job gain.  Two of these subsectors-research, testing, and medical labs and drugs and pharmaceuticals-have led growth during the 2-year period with both increasing employment by more than 3 percent.

Indiana’s bioscience industry is recognized again for being large, highly specialized, and standing out in its diversity.  In keeping with findings from recent studies and reports from BioCrossroads, Indiana’s industry has grown by 1.4 percent since 2012 with especially large job gains in drugs and pharmaceuticals. Indiana’s research universities combine to conduct nearly $582 million in bioscience-related R&D. Indiana has been increasing its bioscience patents, which reflect the diversity of the industry with medical devices, agricultural biosciences, biochemistry, and drugs and pharmaceuticals all represented as areas of focus.  Indianapolis-Carmel-Anderson and Lafayette-West Lafayette, IN Metropolitan Statistical Areas are recognized as being specialized in four of the five bioscience subsectors, with Bloomington and South Bend-Mishawaka Metropolitan Statistical Areas recognized as being specialized in three subsectors.

The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds this ecosystem rebounding but with mixed results.  The U.S. is experiencing strong gains in bioscience venture capital funding and patents, but a slowdown in bioscience-related university R&D expenditures and declining research funding from the National Institutes of Health (NIH).

In addition to examining the economic value of bioscience innovation, the report takes a focused look at the value of this innovation to patients illustrated via two case studies for patients with lung cancer and Type 2 diabetes.  The value of bioscience innovation is evident in quality of life improvements achieved over the last three decades, but there is more to be done.

“This report highlights the long-term expansion of our industry and the significant impact of the high-paying jobs that come with developing the innovative technologies that are helping to heal, fuel and feed the world. These biotech jobs are a critical economic component to states and local communities across the nation,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization. “While the bioscience industry has continued to grow, our analysis shows it is not immune to market realties. State-level legislative and regulatory policies directly impact the innovation that brings research from the lab to the marketplace, and BIO will continue to advocate for effective public policy at every level of government.”

“The bioscience industry continues to prove its economic value by driving U.S. economic growth through innovation, but beyond this economic value, the industry is contributing value to patients every day through improvements to their quality of life,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.

The state-by-state industry assessment is the seventh in a biennial series, developed in partnership by  TEConomy and  BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.

Additional highlights from the industry economic analysis include:
  • Overall industry employment has increased for four consecutive years, and in 2014 all five of the major industry subsectors grew.
  • The industry continues to create and sustain high-wage jobs, reflecting the high skills and education requirements of an innovative workforce, with the average U.S. bioscience worker earning nearly 85 percent more than the private sector average. Bioscience wages have grown substantially faster than overall private sector wages.
  • The industry is a major economic driver and is well distributed across U.S. states and cities:
    • From 2012 through 2014, 35 states experienced net job growth in the biosciences.
    • Thirty-two states and Puerto Rico have an employment specialization in at least one bioscience subsector (at least 20 percent more concentrated than the nation).
    • For U.S. metropolitan areas, 222 of 381 have at least one bioscience specialization.
  • Through strong economic multiplier impacts, each bioscience industry job generates an additional 4.5 jobs in the U.S. economy. The broader employment impact of the 1.66 million U.S. bioscience jobs is an additional 7.53 million jobs throughout the rest of the economy.
Highlights from the analysis of the innovation ecosystem for the bioscience industry include:
  • TEConomy/BIO see strength in recent venture capital and patenting trends:
    • Venture capital investments in bioscience-related companies have increased significantly from a $10.0 billion per year average in 2012-13 to a $14.4 billion per year average in 2014-15.  The investment levels reached in the last two years represent new highs for bioscience-related venture capital.
    • Innovation continues to drive the biosciences, with more than 100,000 U.S. bioscience patents awarded from 2012 through 2015.  During this period, patent volumes continue to trend upward.
  • Signs of stress remain in metrics of federal research funding and academic R&D activity:
    • Overall funding from NIH has declined by 3 percent from 2012 through 2015, despite an uptick in this latest year.  It should be noted that concerns over this stagnate level of NIH funding led Congress to approve a nearly 6 percent increase for NIH in FY 2016.
    • Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has slowed considerably.  From 2012 through 2014, the average annual increase in bioscience-related university R&D was 0.6 percent, while during the preceding 10-year period annual increases averaged 7 percent.
The TEConomy/BIO report includes individual profiles for all 50 states, the District of Columbia and Puerto Rico, and can be found on the BIO website at bio.org/jobs2016.  Indiana’s report is availablehere.

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter.  Subscribe to the BIO Newsletter.

About TEConomy
TEConomy Partners, LLC is a global leader in research, analysis, and strategy for innovation-based economic development. Today we’re helping nations, states, regions, universities, and industries blueprint their future and translate knowledge into prosperity.  The Principals of TEConomy Partners include the authors of the prior Battelle/BIO State Bioscience Development reports, published since 2004.  For more information, please visit http://www.teconomypartners.com.

About IHIF

The Indiana Health Industry Forum is the state affiliate of the Biotechnology Innovation Organization (BIO).  IHIF is a statewide trade association representing members of Indiana’s health science business community.  Our mission is the connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information or to become a member, please visit www.ihif.org.

IHIF Announces Legislators of the Year

May 16, 2016

Recognizes those making significant policy impact on the state’s health science sector

Contact: Kristin Jones, President and CEO
Indiana Health Industry Forum
kjones@ihif.org or 317-686-0994

INDIANAPOLIS, IN (May 16, 2016) — In conjunction with its 2016 Annual Meeting, the Indiana Health Industry Forum (IHIF) recognized U.S. Representative Larry Bucshon, M.D., and State Senator Patricia Miller as the IHIF 2016 Legislators of the Year.  “Each year we recognize federal and state legislators who have demonstrated a commitment to excellence in public health policy and service to Indiana’s health science business community”, said Kristin Jones, President and CEO of IHIF.  “This year we are so pleased to be able to recognize both Representative Bucshon for his work and leadership on the Congressional 21st Century Cures Initiative and Senator Miller for her dedication to health issues and 30 years of public service”.

 

Prior to being elected to Congress, Representative Bucshon spent his career specializing in cardiothoracic surgery and has performed hundreds of heart surgeries.  As one of only a few practicing physicians in Congress his experience with all aspects of health care delivery afford him unique insight and perspective on efforts to improve patient care and seek value across the health care spectrum.  He has been an educated voice of opposition to a proposed CMS rule that would implement a new Medicare Part B drug payment model that would negatively affect patient access to essential medication and treatment therapies.   He has also been a leader in the fight against opioid abuse, working with Representative Paul Tonko (D-NY) to introduce, “The Opioid Use Disorder Treatment Expansion and Modernization Act”.

 

Senator Patricia Miller announced earlier this year that she would be retiring from the state legislature after more than 30 years.  Her outstanding efforts as Chair of the Senate Committee on Health and Provider Services have led to policies that have touched and improved the lives of countless Hoosiers. Her commitment to common sense care and high regard for patient dignity are well reflected in her legislative record.

 

“We are proud that Indiana has been so involved, informed, and well represented”, said Jones “and we are pleased to be able to recognize the contributions of Rep. Bucshon and Senator Miller”.   Previous recipients of IHIF’s Legislative Award include: State Representative. Ed Clere (2014), State Senator Brandt Hershman (2014), and U.S. Representative Susan W. Brooks (IN-5) (2015).

Rep. Larry Bucshon Official Photo
U.S. Rep. Larry Bucshon, M.D. (IN-8th)
Member of the House Energy &
Commerce Committee

PatMiller_2013

Senator Patricia Miller (District 32)
Assistant President Pro-Tempore

About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit www.ihif.org

 

###

 

IHIF Annual Meeting Convenes Industry Leaders

May 16, 2016

Cancer Moonshot and Strategic Plan Anchor Agenda

Contact: Kristin Jones, President and CEO
Indiana Health Industry Forum
kjones@ihif.org or 317-686-0994

INDIANAPOLIS (May 9, 2016) — The Indiana Health Industry Forum is kicking-off its 2016 Annual Meeting and conference for the state’s life science industry today.  The event’s opening reception and VIP Dinner will take place at the Alexander Hotel – a Dolce Property in downtown Indianapolis.   For the third year, the reception will feature a student research poster display highlighting some of the biomedical student projects from the McKenzie Center for Innovation and Technology.  Tuesday’s meeting will take place at the Eli Lilly and Co. headquarters in conjunction with the company’s 140th Anniversary celebration.

The conference keynote speaker will be Michael Weingarten, the director of the National Cancer Institute’s SBIR grant program.  His presentation will cover SBIR best practices, a discussion of the agency’s translational services, programs, and awards, tips on writing a successful application, and touch on the agency’s role in the national Cancer Moonshot initiative.  A follow-on panel will further explore Indiana’s Contribution to the Cancer Moonshot.  Panelists will include: Representative Larry Bucshon, M.D, (IN 8th); Dr. Sherry Harbin, Geniphys; Bryan Hannon, American Cancer Society; Dr. Mervin Yoder, IU School of Medicine, and Scott Shortenhaus, Eli Lilly and Co.  The panel moderator will be Deborah Pollack-Milgate with Barnes & Thornburg.

IHIF will also be kicking off Roadmap 2020 and beginning collection of recommendations for the development of the next industry driven strategic plan.  More information on Roadmap 2020 and how to submit recommendations for consideration can be found on the IHIF website at www.ihif.org/pages/roadmap2020.  A panel discussion covering trends in strategic plan topic areas will include remarks from: Sue Ellspermann, Former Lt. Governor of the State of Indiana , Roger Harvey, Bose Public Affairs Group; Alex Smith, Deloitte; Calvin Thomas IV, Ivy Tech Corporate College; and Matthew Waninger, Ph.D., MED Institute.   The panel will be moderated by Eric Marr, Founder and President of Diversity Accords and current chair of the IHIF Board of Directors.

IHIF would like to thank the following sponsors for their support:  Headline Sponsor: Eli Lilly and Co., Gold Sponsors: Barnes & Thornburg and Cook Medical, Silver Sponsors: CAI and Hoosiers Work for Health, Event Sponsors: Konica Minolta and ShareVault.  IHIF would also like to recognize some of our partners: The Catherine Peachey Fund in support of the Komen Tissue Bank, Lodestone Insights, Cabello Associates, and the BIO Business Solutions Program.

About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit www.ihif.org

News Release: Senator Donnelly Honored as BIO Legislator of the Year

April 13, 2016

BIO Logo Horizontal RGB

1201 Maryland Avenue, SW l Ste. 900 l Washington, D.C. l 20024 l 202-962-9200

Web: www.bio.org  Blog: www.biotech-now.org  Twitter: @IAmBiotech

For Immediate Release Contact: George Goodno
202-962-9660

Senator Donnelly Honored as BIO Legislator of the Year

Washington, D.C. (April 12, 2016) – The Biotechnology Innovation Organization (BIO) announced today its selection of Senator Joe Donnelly (D-IN) as a Legislator of the Year for 2016. Senator Donnelly receives the award in conjunction with BIO’s Legislative Day Fly-In.

“Senator Donnelly has been a steadfast champion on the issues that matter to our industry. BIO thanks Senator Donnelly for his support of biotechnology in human and animal health, in food and agricultural production, and in generating renewable fuels and bio-based products,” said BIO President and CEO Jim Greenwood. “Through his seats on the Senate Committee on Agriculture, Nutrition and Forestry, the Senate Special Committee on Aging and the Senate Committee on Armed Services, the Senator is a strong and effective leader for the innovation community. We thank him in particular this year for his efforts to find a bipartisan federal solution to prevent a state-by-state patchwork of bioengineered food labeling laws that would upend the American food value chain.”

“As a champion for the thousands of Hoosiers working in the biotechnology industry, Senator Donnelly has demonstrated leadership on issues vitally important to our state and the nation,” said Kristin Jones, President and CEO of the Indiana Health Industry Forum. “The life science industry in Indiana provides an enormous economic impact and provides jobs, both directly and indirectly, for over 57,000 people. We thank Senator Donnelly for his engagement and dedication to the innovative capacity and job creating potential of life science companies, and congratulate him on receiving this award.”

More than 200 biotechnology industry representatives from over 40 states, representing hundreds of thousands of American workers, will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In. Participants will discuss issues critical to the biotechnology industry including, drug development, discovery and delivery reforms, targeting abuses of the U.S. patent system while protecting innovation, providing adequate reimbursement for vital therapies under Medicare, FDA funding, tax policy, support for science-based GMO food labeling solutions and capital formation issues relevant to biotechnology companies.

Photos of the award presentation are available upon request.

About BIO

BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Upcoming BIO Events 

BIO International Convention
June 6-9, 2016
San Francisco, CA

World Congress on Industrial Biotechnology
April 17-20, 2016
San Diego, CA

BIO Investor Forum
October 18-19, 2016
San Francisco, CA

 

 

 

IHIF Welcomes CRI Medical Devices as New Member!

March 14, 2016

CRI - Full logo

CRI is a global full service medical device manufacturer specializing in class I, II & III single-use medical devices, concept development and product life cycle management. With three decades of experience, CRI® has a dedicated staff focused on customer needs to ensure a high level of satisfaction.

Learn more at http://www.cri-devices.com/en